Efeito da erradicação do Helicobacter pylori na resposta plaquetária em adultos com Púrpura Trombocitopênica Imune
uma revisão narrativa estruturada
DOI:
https://doi.org/10.36557/2674-8169.2026v8n2p223-244Keywords:
púrpura trombocitopênica idiopática, Helicobacter pyloriAbstract
Introduction: Immune Thrombocytopenic Purpura (ITP) is an autoimmune disease characterized by peripheral platelet destruction, which can result in hemorrhagic manifestations of varying severity. Recent evidence has demonstrated an association between Helicobacter pylori infection and platelet response in a subgroup of adult patients with ITP. In this context, investigating the role of bacterial eradication emerges as a potentially beneficial therapeutic strategy, justifying the present study. Objectives: To evaluate the association between Helicobacter pylori eradication and platelet response in adults with Immune Thrombocytopenic Purpura (ITP) through a structured narrative literature review. Methodology: A search was conducted in the PubMed, Cochrane Library, and Web of Science databases using the descriptors "Immune Thrombocytopenic Purpura," "ITP," and "Helicobacter pylori," combined using the AND operator. Narrative reviews, systematic reviews, meta-analyses, and clinical trials were included, addressing the therapeutic influence of Helicobacter pylori eradication on the platelet response in adult patients with Immune Thrombocytopenic Purpura. Conclusion: Helicobacter pylori infection plays a relevant role in the pathophysiology of Immune Thrombocytopenic Purpura in a subgroup of adult patients. Bacterial eradication is associated with improved platelet counts and a reduction in hemorrhagic manifestations in a significant proportion of cases, representing a safe, low-cost, and potentially beneficial therapeutic strategy.
Keywords: Idiopathic thrombocytopenic purpura, Helicobacter pylori, hematology.
Downloads
References
GASBARRINI A, et al. Helicobacter pylori eradication induces platelet recovery in patients with idiopathic thrombocytopenic purpura. Gut, 1998; 43(3): 370–372.
KUWANA M. Helicobacter pylori-associated immune thrombocytopenia: clinical features and pathogenic mechanisms. World Journal of Gastroenterology, 2014; 20(3): 714–723.
FRANCHINI M, et al. Helicobacter pylori-associated immune thrombocytopenia: a systematic review and meta-analysis. Journal of Thrombosis and Haemostasis, 2007; 5(12): 2467–2474.
FRANCHINI M, VENERI D. Helicobacter pylori-associated immune thrombocytopenia: an update. World Journal of Gastroenterology, 2010; 16(42): 5314–5320.
TAN HJ, GOH KL. Extragastric manifestations of Helicobacter pylori infection: facts or myth? World Journal of Gastroenterology, 2012; 18(29): 3374–3381.
KIM BJ, et al. Effect of Helicobacter pylori eradication on immune thrombocytopenic purpura: a meta-analysis of randomized controlled trials. Helicobacter, 2018; 23(2): e12462.
IHTESHAM K, et al. Helicobacter pylori induced immune thrombocytopenic purpura: a review of the literature. AIMS Microbiology, 2021; 7(3): 270–285.
STASI R, et al. Pathophysiology and therapeutic approaches to immune thrombocytopenia. Haematologica, 2009; 94(8): 1124–1133.
SAITO K, et al. Anti-platelet glycoprotein antibodies in immune thrombocytopenic purpura. International Journal of Hematology, 2011; 93(4): 463–469.
SMYK DS, et al. Helicobacter pylori and autoimmune disease: cause or bystander? World Journal of Gastroenterology, 2014; 20(3): 613–629.
CINES DB, BLANCHETTE VS. Immune thrombocytopenic purpura. New England Journal of Medicine, 2002; 346(13): 995–1008.
NEUNERT C, et al. The American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Advances, 2019; 3(23): 3829–3866.
MICHAELI J, et al. Mechanisms of platelet destruction in immune thrombocytopenia. Seminars in Hematology, 2013; 50(1): S13–S18.
MOORE PS, et al. Chronic infection and immune-mediated platelet destruction. Clinical Reviews in Allergy & Immunology, 2008; 34(1): 71–80.
WROBEL T, et al. Long-term follow-up of immune thrombocytopenia patients after Helicobacter pylori eradication. Platelets, 2016; 27(4): 357–361.
ZHU F, et al. Helicobacter pylori infection and immune thrombocytopenia: a systematic review and meta-analysis. Platelets, 2019; 30(6): 697–703.
S17. TASI R, PROVAN D. Helicobacter pylori and immune thrombocytopenia. Journal of Thrombosis and Haemostasis, 2008; 6(2): 326–328.
EMILIOZZI A, et al. Helicobacter pylori eradication and platelet count increase in idiopathic thrombocytopenic purpura. British Journal of Haematology, 2001; 113(2): 403–405.
ASAHI A, et al. Helicobacter pylori eradication shifts monocyte Fcγ receptor balance toward inhibitory FcγRIIB in immune thrombocytopenia patients. Journal of Clinical Investigation, 2008; 118(8): 2939–2949.
SUGIYAMA T, et al. Improvement of thrombocytopenia after Helicobacter pylori eradication in patients with immune thrombocytopenic purpura. Annals of Internal Medicine, 2005; 143(5): 385–386.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Taynah Maria Aragão Sales Rocha, Dr. Evandro Oliveira Galvão Filho, Lucas Pinheiro Brito
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors are copyright holders under a CCBY 4.0 license.
